Ergoteles’s Titan Pharmaceuticals TTNP Stock Holding History

Ergoteles’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-949	Closed	-$11K	–	1996
2022 Q2	$11K	Buy	+949	New	+$11.8K	﹤0.01%	1590

Other funds holding TTNP

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ergoteles's TTNP Position: Q3 2022 in Review

Ergoteles sold out of Titan Pharmaceuticals (TTNP) in Q3 2022, closing a stake of 949 shares — an estimated $11K sold.

Ergoteles first reported a position in TTNP in Q2 2022 and held it in 1 quarter. The position peaked at $11K in Q2 2022. 18 funds tracked by Wall St. Rank hold TTNP as of Q3 2022.

Ergoteles reported no remaining Titan Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 949 Titan Pharmaceuticals shares in Q3 2022, an estimated $11K.
Ergoteles first reported a position in Titan Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Ergoteles's Titan Pharmaceuticals position peaked at $11K in Q2 2022.
18 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.